Loading
A phase 2 trial of Nivolumab in ovarian cancer, run by USWM CT, LLC, active and no longer recruiting.
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) is a phase 2 interventional study registered as NCT05601752 by USWM CT, LLC, with 66 participants planned, started 2023-06-26 and due to reach its primary completion in 2026-08-12. Interventions recorded: Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.